Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months
Options
BORIS DOI
Publisher DOI
PubMed ID
23066911
Description
While rifaximin was able to improve symptoms in patients with irritable bowel syndrome (IBS) in phase III trials, these results are yet to be repeated in phase IV studies.
Date of Publication
2012
Publication Type
Article
Subject(s)
600 - Technology::610 - Medicine & health
Language(s)
en
Contributor(s)
Meyrat, P | |
Schoepfer, A M |
Additional Credits
Institut für Sozial- und Präventivmedizin (ISPM)
Series
Alimentary pharmacology & therapeutics
Publisher
Wiley-Blackwell
ISSN
0269-2813
Access(Rights)
restricted